Objective: To describe the experience managing treatment-refractory immune-mediated necrotizing myopathies (IMNM) with high-dose cyclophosphamide (HiCy) therapy.
Some patients with myositis may be resistant to standard immunosuppressive regiments, including prednisone, methotrexate, azathioprine, IV immunoglobulin (IG), rituximab, and/or other medications. In such patients, especially those with a progressive clinical course, additional therapies may be required. High-dose chemotherapy followed by stem cell rescue through autologous stem cell transplantation (ASCT) has been previously used with some success in patients with refractory myositis. [1] [2] [3] However, given the risks associated with ASCT, highdose cyclophosphamide (HiCy) without bone marrow transplantation can also be considered. First used for treatment of severe aplastic anemia, 4, 5 HiCy has subsequently been applied to several rheumatologic and neurologic diseases. [6] [7] [8] [9] [10] As HiCy seems to be better tolerated than ASCT and yet induces a high rate of remission in refractory autoimmune diseases, 11 we have used it to treat a number of patients with refractory myositis at the Johns Hopkins Myositis Center. 12 In this case series, we report the clinical response of 5 patients who underwent HiCy therapy for refractory immune-mediated necrotizing myopathy (IMNM), a particularly severe form of myositis that predominantly affects skeletal muscle.
METHODS This is a retrospective case series review of 5 patients with IMNM who were treated with HiCy at the Johns Hopkins Myositis Center. The Johns Hopkins Institutional Review Board approved this study. All patients had been evaluated as part of routine clinical care between 2009 and 2016. The patients were administered cyclophosphamide at a dose of 50 mg/kg of ideal body weight IV every day for 4 consecutive days. The method of administering HiCy and the posttreatment supportive care has been previously described. 13 Bilateral arm abductor and hip flexor muscle strength was graded using a 0-5 modified Medical Research Council scale and subsequently transformed to the 10-point Kendall scale and summed together for a score range of 0-40 as previously described 14 and included in the Supplementary Materials. This transformation has not been validated. Definite responders were defined as those who both (1) improved by at least 2 grades in either the upper or lower extremities and (2) were able to taper their prednisone dose below 10 mg/d. Nonresponders were defined as patients who received therapy without improved muscle strength or ability to taper prednisone. Follow-up for patients after HiCy administration was at the discretion of the primary treating rheumatologist and neurologist. Most patients were followed at 2-3-month intervals. Table 1 summarizes demographic features, clinical characteristics, and immunosuppressive  therapies in 5 patients. Tables 2 and 3 summarize  muscle A 53-year-old African American man presented with a 4-month history of progressive upper and lower extremity weaknesses, dyspnea on exertion, and dysphagia. His initial CK level was greater than 9,000 IU/L, and he had muscle strength grade 3/5 in proximal upper and lower extremities. Electromyography demonstrated an irritable myopathy, and muscle biopsy showed severe necrotizing myopathy. Lower extremity MRI showed atrophy and muscle edema. Antibodies against signal recognition particle (SRP) were detected in this patient's serum. He was treated with corticosteroids and methotrexate with minimal improvement. Azathioprine, mycophenolate mofetil, and IVIG treatment yielded temporary improvement in muscle strength, but worsening dysphagia and muscle pain. He was subsequently treated with ACTH gel (corticotropin injection), rituximab, and tacrolimus with no substantial improvement in his symptoms. Given the refractory nature of his disease, the patient was treated with HiCy. He tolerated the treatment well, but 9 days after discharge, he was admitted to the hospital with neutropenic fever and treated for pneumonia. In the ensuing 2 months, he experienced marked improvement in muscle strength, and his CK level decreased from 2,000 to less than 500 IU/L. The patient was completely weaned off immunosuppressive therapy, and 3 month later, his muscle strength was graded 5/5 in both upper and lower extremities and his CK level normalized. Her proximal upper extremities were graded as 4/5 and lower extremities 42/5. She was initially treated with azathioprine and prednisone 60 mg daily without effect. She subsequently received methotrexate and IVIG (2 g/kg), but despite these therapies, she had persistent weakness, and her CK level remained 2,000-3,000 IU/L. She received rituximab with suppression of her CD19/CD20 cell populations, after which her CK actually increased to 6,000 IU/L. TOXICITY All 5 patients tolerated the HiCy regimen well. All patients experienced mild side effects including nausea and alopecia. Neutropenic fever was observed in 4 patients within 2-3 weeks after receiving HiCy, but all recovered. One patient (patient 3) experienced a prolonged hospital stay of 25 days after HiCy for treatment of C difficile colitis and fungal pneumonia. At the time of this report, no patient experienced hemorrhagic cystitis or malignancy. There were no fatalities.
RESULTS
DISCUSSION In this study, we have described our experience treating patients with severe refractory IMNM with HiCy without stem cell rescue. The 2 definite responders (patients 1 and 2) had substantial improvement in muscle strength and decreased requirement for corticosteroids after treatment. Nonresponders included patients 3, 4, and 5 who had no improvement in strength or ability to taper immunosuppression. Patient 3 had initial improvement with subsequent return to pre-HiCy status. Patient 4 initially demonstrated partial response but then worsened, prompting treatment with rituximab, after which he demonstrated improvement. In all cases, the adverse effects were manageable and comparable with those observed in previous HiCy studies. 6 ,15 Although 4 of the 5 patients required hospitalization for neutropenic fever and/or infection, the high risk of this side effect was anticipated and considered warranted, given the limited additional treatment options and the potential benefit of HiCy. This series suggests that HiCy may be effective in select patients with treatment-refractory IMNM.
IMNM is sometimes associated with unique autoantibodies, including anti-SRP (patients 1-3) and anti-HMGCR autoantibodies (patients 4-5), and a distinct clinical phenotype. 16, 17 Anti-HMGCR myopathy is characterized by prominent myofiber necrosis on biopsy and very high CK levels. 16, 18 Similarly, patients with anti-SRP antibodies frequently present with markedly elevated CK levels and a necrotizing myopathy without primary inflammation. 17, [19] [20] [21] Although it is interesting that both patients who responded to HiCy were anti-SRP positive, the numbers included in this study are too small to conclude whether autoantibody status can predict response to this therapy.
Regarding the 3 patients with anti-SRP antibodies, 2 experienced dramatic improvement, whereas the third had initial improvement with subsequent worsening at the time of this report. Notably, the patient who worsened also had anti-Ro autoantibodies. Other groups have noted that in rheumatologic conditions such as systemic lupus erythematosus and scleroderma, the presence of anti-Ro autoantibodies portends a poorer prognosis 22, 23 and in myositis has been associated with earlier and more severe disease. [24] [25] [26] A review of the literature suggests that despite an initial response rate, most patients with severe autoimmune disease ultimately relapse following HiCy therapy with only 20% remaining disease free 5 years after treatment. 12 However, it should be noted that patients with myositis were not included in those studies. We acknowledge that this therapy carries a higher risk of infection and morbidity, especially when taking into account a potential high relapse rate as seen in other autoimmune conditions treated with this regimen. Furthermore, long-term risk regarding malignancy must be taken into account, given its association with some necrotizing myopathies. 27, 28 However, for patients who have failed conventional therapies for necrotizing myopathy (i.e., rituximab and IVIG), we believe that this therapy offers another option for the clinician to consider who otherwise has very few options.
Although follow-up of patients with myositis in the current study was limited to an average of 3 years (median 37 6 28 months, range 7-72 months), the 2 responders have now been followed without relapse for 34 and 72 months, respectively. Additional study and follow-up time will be needed to further assess the true duration of remission.
A strength of this study is that all 5 patients underwent the same HiCy protocol at a single center. In addition, all have had longitudinal follow-up in the same center. Limitations of the study include its retrospective nature and the small number of patients. Furthermore, as this study was not protocol driven, follow-up was not uniform and at the discretion of the treating physician. Additionally, many patients were treated with concurrent medications; however, they were on stable doses for months preceding the administration of HiCy. As such, the likelihood that the patients had a delayed response to their background immunosuppressive medications is unlikely.
Although numerous therapies have been shown to be effective for the treatment of inflammatory myopathies, treatment of refractory cases, particularly IMNM, remains challenging. 29 The data presented here reveal that HiCy may represent a potential therapeutic alternative in IMNM patients with refractory disease. 
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